NIASPAN 750 MG — DIN 02262355
NICOTINIC ACID : 750 MG · SUNOVION PHARMACEUTICALS CANADA INC · TABLET (EXTENDED-RELEASE) · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is NIASPAN?
NIASPAN 750 MG contains NICOTINIC ACID : 750 MG. It is listed in the Health Canada Drug Product Database under DIN 02262355, held by SUNOVION PHARMACEUTICALS CANADA INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 02-Aug-2012. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is NIASPAN used for?
Adjunct to diet to reduce TC, LDL-C, Apo B, and TG levels, and to increase HDL-C in patients with primary hypercholesterolaemia and mixed dyslipidaemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Nicotinic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Nicotinic Acid — 6 DINs, of which 0 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SUNOVION PHARMACEUTICALS CANADA INC | 6 | 0 | NIASPAN, NIASPAN FCT | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 750 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | 500 mg, 750 mg, 1000 mg extended-release tablets (specific container details not provided in text). |
| Storage | Not explicitly specified in provided text (refer to STORAGE AND STABILITY section 17). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Nicotinic Acid |
|---|---|
| ATC code | C10AD02 |
| AHFS class | 24:06.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02262355 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2262355 |
| Brand name | NIASPAN |
| Generic / active ingredient | NICOTINIC ACID : 750 MG |
| Market authorization holder | SUNOVION PHARMACEUTICALS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | C10AD02 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C10AD |
| Current status | CANCELLED POST MARKET |
| Status date | 02-Aug-2012 |
| Original market date | 2005-03-15 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Take at bedtime after a low-fat snack. Initiate at 500 mg; titrate by max 500 mg every 4 weeks to a maintenance dose of 1000-2000 mg. Tablets must be swallowed whole.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to niacin; active liver disease; unexplained persistent elevations of serum transaminases; active peptic ulcer; active bleeding.
Warnings and precautions
Do not substitute for immediate-release niacin. Risk of severe hepatic toxicity. Monitor liver tests and blood glucose. Rare cases of rhabdomyolysis when used with statins.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 6 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| NIASPAN | 1000 MG | TABLET (EXTENDED-RELEASE) | SUNOVION PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 02262339 |
| NIASPAN | 500 MG | TABLET (EXTENDED-RELEASE) | SUNOVION PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 02262347 |
| NIASPAN FCT | 500 MG | TABLET (EXTENDED-RELEASE) | SUNOVION PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 02309254 |
| NIASPAN FCT | 750 MG | TABLET (EXTENDED-RELEASE) | SUNOVION PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 02309262 |
| NIASPAN FCT | 1000 MG | TABLET (EXTENDED-RELEASE) | SUNOVION PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 02309289 |
2 · Same class — other molecules in ATC C10AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Nicotinic Acid | NIASPAN · NIASPAN FCT | 6 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C10AA | Atorvastatin · Cerivastatin · Fluvastatin · Lovastatin · Pravastatin · +2 more | 759 | 286 |
| C10AX | Alirocumab · Dextrothyroxine · Evinacumab · Evolocumab · Ezetimibe · +5 more | 48 | 28 |
| C10AB | Bezafibrate · Clofibrate · Fenofibrate · Gemfibrozil | 87 | 13 |
| C10AC | Colesevelam · Colestipol · Colestyramine | 29 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is NIASPAN called?
The same molecule, Nicotinic Acid, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Niacin | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Nicotinic Acid called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Nicotinic Acid, published to help those searches reach this page.
| Language | Nicotinic Acid |
|---|---|
| Arabic العربية | حمض النيكوتينيك |
| Chinese (Simplified) 简体中文 | 烟酸 |
| Russian Русский | Никотиновая кислота |
| Spanish Español | Ácido nicotínico |
| French Français | Acide nicotinique |
| Portuguese Português | Ácido nicotínico |
| German Deutsch | Nicotinsäure |
| Japanese 日本語 | ニコチン酸 |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.